Guggenheim Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $50
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Buy rating and announces Price Target of $50.
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Buy rating and announces Price Target of $50.